Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells-Reference-Cited by-同舟云学术

Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells

Published:2015-12-30 Issue:4 Volume:20 Page:281-286
ISSN:2288-3649
Container-title:Journal of Cancer Prevention
language:en
Short-container-title:J Cancer Prev

Author:

Lee Sun Kyoung¹²,Park Kwang-Kyun¹²,Kim Ki Rim³,Kim Hyun-Jeong¹²,Chung Won-Yoon¹²

Affiliation:

1. Department of Oral Biology, Oral Cancer Research Institute, BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, Korea,

2. Department of Applied Life Science, Yonsei University Graduate School, Seoul, Korea

3. Department of Dental Hygiene, College of Science and Technology, Kyungpook National University, Sangju, Korea

Publisher

Korean Society of Cancer Prevention

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

http://pdf.medrang.co.kr/Jkacp2/020/jcp-20-276.pdf

Reference26 articles.

1. Metastasis to bone: causes, consequences and therapeutic opportunities

2. Theriault, RL, and Theriault, RL (2012). Biology of bone metastases. Cancer Control. 19, 92-101.

3. Mechanisms of cancer cell metastasis to the bone: a multistep process

4. Bone metastasis: mechanisms and therapeutic opportunities

5. Targeting RANKL in metastasis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An insight into the therapeutic effects of isoliquiritigenin in breast cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-15

2. Isoliquiritigenin induced endoplasmic reticulum stress in zebrafish embryos;2024-04-11

3. Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence;International Journal of Molecular Sciences;2023-06-19

4. Effect of particle size on the oral absorption of isoliquiritigenin nanocrystals;Brazilian Journal of Pharmaceutical Sciences;2022

5. TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis;Current Pharmaceutical Biotechnology;2021-02